Alle Storys
Folgen
Keine Story von Euromed AG mehr verpassen.

Euromed AG

euro adhoc: Euromed AG
Quarterly or Semiannual Financial Statements
EUROMED AG Announces Financial Data for the First Half of 2002 (E)

Disclosure announcement transmitted by euro adhoc. The issuer is
responsible for the content of this announcement.
Fürth, July 23, 2002. EUROMED AG (WKN 570680), operators of a private
high performance clinic and consultant in the field of quality
management, finished the 2nd quarter with consolidated earnings of
10,075,000, or approximately 2.5% below the comparable period for the
previous year.
The consolidated pre-tax earnings (EBT) retreated to
-373,000 (same period last year: +573,000). Cost savings are
proceeding as planned. It was entirely due to the expansion work that
space costs had an overall negative effect on the cost situation.
Despite the sales and returns development to date, the company’s
liquid assets increased from 444,000 to 1,003,000 during the
reporting period and based on the valuation date.
In the EuromedClinic business area, EUROMED AG continues to
concentrate its efforts on the dispute with the Association of
Private Health Insurers regarding the appropriate clinical rates.
Based on the difficult market conditions overall and the development
during the first half of 2002, it can be assumed that the figures for
the fiscal year with regard to sales and returns will be below
previous year values.
end of announcement        euro adhoc 23.07.2002

Further inquiry note:

Harald Niebler, Investor Relations, EUROMED AG, www.euromed.de Tel: (+49) 911 / 9714-604,
Fax: (+49) 911 / 9714-607, e-mail: boerse@euromed.de

Branche: Healthcare Providers
ISIN: DE0005706808
WKN: 570680
Börsen: Frankfurter Wertpapierbörse / regulated dealing

Weitere Storys: Euromed AG
Weitere Storys: Euromed AG